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Aim was to investigate fracture risk (FR) according to bone loss (BL) rate. A random sample of 1652 women aged 53.5 years was
measured with dual X-ray absorptiometry in femoral neck in 1989 and 1994 and divided into tertiles of annual BL rate: high
>0.84%, moderate 0.13%–0.84%, and low <0.13%. Low trauma energy fractures during following 10 years were recorded. There
were no diﬀerences in FR between BL tertiles in Cox regression model. Factors predicting lower FR in Cox model were in high
tertile: high T-score (HR 0.71; 95% CI 0.54–0.93, P = .012), no sister’s fracture (HR 0.35; 0.19–0.64, P = .001), no mother’s
fracture (HR 0.52; 0.31–0.88, P = .015), in moderate tertile: high T-score (HR 0.69;0.53–0.91, P = .008) and good grip strength
(HR 0.98; 0.97–0.99, P = .022). In low tertile there were no predictors for FR. BL predicted FR in women with mother’s fracture
in univariate and multivariate model (OR 2.6; 1.15–5.7, P = .021) but with sister’s fracture this was observed only in multivariate
model (OR 2.66; 1.09–6.7, P = .039). Accordingly, the risk factors for postmenopausal fractures, especially mother’s fracture, may
interact with BL.
1.Introduction
Osteoporotic fractures result in signiﬁcant morbidity and
mortality [1, 2]. The risk of fractures is greater among
women with low BMD although it has now been accepted
that diﬀerences in BMD and its changes explain only part
of the increased fracture tendency among the elderly [3].
Other parameters of bone quality may be more impor-
tant measures of fragility [4, 5]. Overall, the individual
fracture risk is a sum of falling propensity and bone
material quality and accordingly may be modiﬁed by genetic
predisposition and several external environmental risk
factors.
The diagnosis of osteoporosis is currently based on
central DXA. Moreover, it has been emphasized that several
non-BMD dependent risk factors should be taken into
account while considering individual risk of fractures [6].
Accordingly, the recent trends in both clinical as well as
research ﬁelds have favored a holistic and individually
tailored approach to increased bone fragility instead of
concentratingonlyonfracturesrelatedtoosteoporoticBMD.
Asanexample,atoolfortheidentiﬁcationof10-yearfracture
risk, FRAX, has been recently introduced for clinical use,
which combines independent risk factors for fractures with
BMD [6].
Several studies have investigated the risk factors for
osteoporotic fractures [7–13]. According to these studies, the
most important environmental risk factors for low-trauma
energy postmenopausal fractures are low BMD, previous
fracture history, body composition, menopausal transition,
excessive alcohol consumption, and smoking [7–12]. In
addition, a family history of fractures has been suggested to
be associated with increased postmenopausal risk of bone
fragility in number of epidemiological studies [13–18].2 Journal of Osteoporosis
Previous studies have shown that the most cases of
fragility fractures occur not among osteoporotic but among
osteopenic women [19]. These ﬁndings reveal that there is
more to postmenopausal bone fragility than BMD alone.
However, no long-term population-based study has so far
directly explored the diﬀerences in risk factors for fragility
fractures according to rate of bone loss. The rationale for
such a study would be the identiﬁcation of risk factors
for “high bone loss fragility disease” versus “other types
of bone fragility disease”. In addition, the clinical tools for
fragility fractures use cross-sectional or past information
for evaluation of long-term fracture risk, which raises the
question of whether changes in BMD or other risk factors in
due course would signiﬁcantly aﬀect the estimated fracture
risk. Accordingly, epidemiological data on eﬀects of BMD
change rate in conjunction with other risk factors for
fractures is needed.
The aim of the present study was to identify the risk
factors for perimenopausal low-trauma energy fractures
according to bone loss rate. The primary hypothesis was that
risk factors that account for low-trauma energy fractures in
w o m e nw i t hh i g ha n dl o wb o n el o s sr a t e sa r ed i ﬀerent.
2.MaterialsandMethods
2.1. Study Population and Study Frame. The study pop-
ulation was formed based on the prospective Kuopio
Osteoporosis Risk Factor and Prevention (OSTPRE) study
cohort. The OSTPRE cohort was established in 1989 by
selecting all women born in 1932–1941 and resident in
Kuopio Province, Finland (n = 14 220) [20]. The baseline
postal inquiry, including questions, for example, about
health disorders, medication, use of hormone therapy (HT),
gynaecological history, nutritional habits, calcium intake,
physical activity, alcohol consumption, smoking habits, and
anthropometric information, was sent to these women at
baseline in 1989. The ﬁve-year (in 1994), ten-year (1999),
and 15-year (2004) followup questionnaires were sent to the
13100 women who responded at baseline. Of these women,
11954 responded to postal inquiry in 5-year, 11537 in 10-
year, and 10926 in 15-year followup. Albeit the study design,
and selection of the random sample, was prospective, the
presentstudywasperformedbystratifyingthestudygroupof
interest, described below in detail, retrospectively. The postal
inquiries included informed consent from the participants
and the study protocol has been accepted in the ethics
committee of University of Kuopio and Kuopio University
Hospital.
The selection of the present study population and study
protocol is outlined in Figure 1. Of the 13100 respondents
to baseline postal inquiry in 1989, 11055 (84.4%) reported
willingness to undergo DXA densitometry. A densitometry
sample of 3686 women (33.3%) was invited to the base-
line DXA measurements while rest of the 11055 women
were not measured at all. Out of the women invited to
DXA, 3222 (87.4%) women actually underwent the baseline
measurement (i.e., 464 of the invited women did not
participate at all). The women that actually underwent
the baseline DXA were divided into two groups: random
population-based sample consisted of 2025 women and the
remaining 1197 women formed a nonrandom part which
was stratiﬁed for other study purposes or were labeled to
have a high-risk proﬁle (i.e., experienced menopause within
2 years, had certain diseases/medications aﬀecting bone, had
multiple behavioral risk factors, were selected for an HT +
vitamin D trial, or were included in additional rheumatoid
arthritis sample [21, 22]). Accordingly, the non-random part
(n = 1197) was excluded from the present study. In all,
1873 women of the random part underwent 5-year follow-
up bone density DXA measurement (i.e., DXA dropout
n = 152). Serial valid measurements for neck of femur
were recorded for 1783 women in both baseline and the
5-year follow-up measurement. Accordingly, severe bone
deformities, including deforming arthritis, and prostheses
among other inaccuracies, (n = 90) were excluded by a
systematic manual review of densitometry reprints by the
study-group physicians.
Hysterectomized women and premenopausally bilater-
ally ovariectomized women were included in the study sam-
ple but women with unclear transition to postmenopause
(either surgical or natural) were excluded (n = 131). The
beginning of menopause was deﬁned in this study as 12
months’amenorrhea[23].Thebeginningofamenorrheawas
based on self-reports about the last natural periods in the
inquiries and no hormonal samples were collected in this
respect. Accordingly, the ﬁnal study population consisted of
a random sample of 1652 perimenopausal women aged 53.5
(SD 2.9) years at the beginning of the study (year 1989)
(Figure 1).
The present study population was divided into tertiles
according to bone loss rate based on annual change in BMD
(%) between baseline and 5-year follow-up measurements
(Figure 1). The bone loss rate during the ﬁrst 5-year follow-
up was used for prediction of the following 10-year (5-
to 15-year) fracture risk and an other 5-year measurement
and postal inquiry risk-factor information were used as
additional predictive data.
2.2.Fractures. Fracturesduringthe15-yearfollow-upperiod
(1989–2005) were recorded based on questions (in baseline,
5-year, 10-year, and 15-year follow-up postal questionnaires)
on whether the respondent had suﬀered a low-trauma
energy fracture during the follow-up and, if so, the type,
mechanism, circumstances, and treatment of the fracture.
All self-reported fractures were validated by cross-checking
radiological reports from medical records by study-group
physicians. However, rib fractures were accepted without
radiological evidence if the clinical diagnosis in the medical
records was clearly and uniformly a rib fracture. For
the present study, only low-trauma energy fractures were
accepted, that is, stumbling, tripping, slipping, or falling
under 1-meter height. The false positive rate in self-reported
fractures was 16.5% and the false negative rate was 21.6%,
respectively [24]. Because the prospective fracture follow-
up of the present study was from 5- to 15-year follow-up,
the fractures during the ﬁrst follow-up interval (i.e., baseline
to 5 years) were considered past fractures in multivariate
models.Journal of Osteoporosis 3
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bone densitometry
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Study groups according to annual bone
loss rate (%) tertiles∗:
High: over 0.84%/ year
Moderate: 0.84 to 0.13%/ year
Low: under 0.13%/ year
∗Bone loss rate determined between baseline to 5 years followup
Figure 1: Study groups and study protocol (n = 1652).
History of fractures of the ﬁrst-degree relatives was
inquired by the following questions: “have your mother
suﬀered a fracture of wrist or hip or both?” and “Have
your sister suﬀered a fracture of wrist or hip or both?”.
Sister’s and mother’s fractures were treated as separate
dichotomous (fracture/no fracture) variables in the analyses
and all fractures either before or during the 15-year follow-
up were taken into account. Accordingly, the either relatives
fracture was considered from the view of genetics rather than
an “a priori” risk factor. Also, the mother’s and sister’s wrist
and hip fracture history was not questioned earlier than 10-
year follow-up postal inquiry. The exact types/classiﬁcation
of relatives’ fractures or trauma energy were not more
speciﬁcally questioned and accordingly we were not able to
consider this issue in the present study in more details. In
statistical analyses women without conﬁrmation of having
a sister were considered missing values. The fractures of
the father and brother(s) were also inquired with separate
question, but not included in the analyses of the present
study, because of insuﬃcient number of fractures of these
speciﬁc relatives for statistical purposes.
2.3. Other Variables of Interest. The height and weight of
each study subject were measured with calibrated scale in
the presence of study-group nurses at the time of each bone
densitometry. The body mass index (BMI) was calculated as
weight/height2 (kg/m2) in each follow-up measurement.
The use of hormone therapy (HT) was calculated based
on the self-reported use of oestrogen containing tablets and
patches and used for menopausal symptoms, which was
speciﬁcally questioned in the inquiries. Three groups were
formed according to menopause status and the use of HT
during the menopausal transition: (1) premenopausal group
of women who were premenopausal at 5-year measurement
(year 1994) and underwent the menopausal transition
during the 5- to 15-year follow-up but had not used HT,4 Journal of Osteoporosis
(2) postmenopausal g r o u po fw o m e nw h ow e r ep o s t -
menopausal in 5-year measurement but had not used HT,
and (3) HT users that included all women reporting use
of HT for menopausal symptoms. This three category
menopause variable was used as covariate in statistical mod-
els. The validation of self-reported use of HT with national
medical prescription records has shown good correlation
(98% of HT users were true users) and has been described
in detail previously [25].
Grip strength, measured with pneumatic hand-held
dynamometer (Martin Vigorimeter, Germany), was taken to
bethemeanofthreesuccessivemeasurements.Themeasure-
ments were done in controlled sitting position by trained
nurses. Grip strength change was determined by change
in age-adjusted grip strength quartile between baseline
and 5-year measurements, because the measurement device
was changed during the follow-up period. The intraclass
correlation coeﬃcient (ICC) of grip strength measurements
has been shown to be 0.87 and for grip strength change
measurements 0.85 [26]. The grip strength measurement
protocol, and the validation of use of age-adjusted quartiles
for grip strength change estimation, of the present study has
been described in more detail previously [26].
The alcohol intake (g/week) was calculated based on the
following question: “how many drinks of beer/wine/spirits
do you consume monthly on average?” in postal inquiries.
The information on smoking was based on following
questions: “have you ever smoked (cigarettes, pipe, etc.)?”
and “do you smoke currently?” It was used as a dichotomous
covariate in statistical models: (1) no smoking and (2) any
smoking. The calcium intake of each participant was calcu-
lated according to self-reported ingestion of milk products in
postal inquiries. The following questions were asked: “how
many decilitres of ﬂuid milk products (milk, sour milk,
yoghurt, etc.) do you consume daily? ”, and “how many slices
of cheese do you eat daily?” The amount of calcium was
approximated to be 120mg/dl for ﬂuid milk products and
87mg/slice for cheese.
2.4. Bone Mass Measurements. The DXA measurements of
anterior-posterior spine (L2-L4) and femoral neck were
carried out using the same Lunar DPX scanner in both
baseline and 5-year measurements with the imaging and
analysis protocols provided by the manufacturer (Lunar
Co. Madison, WI, USA) and described earlier [21]. The
measurements were carried out in Kuopio University Hos-
pital by specially trained nurses. Quality standards were
tested on daily basis. The short-term reproducibility of this
method has been shown to be 0.9% for lumbar spine and
1.5% for femoral neck BMD measurements [27]. The long-
term reproducibility (CV) of the DXA instrument for BMD
during the study period, as determined by regular phantom
measurements, was 0.4% [22]. For the purposes of the
present study, BMD was converted into T-score according to
theFinnishreferencevalues,alsoadoptedforclinicaluse,and
described earlier [27].
2.5. Statistical Methods. Statistical analyses were carried
out using the Statistical Package for Social Sciences (SPSS
ver. 15, SPSS Inc., Chicago, Illinois, USA) for Windows.
Kaplan-Meier curves were obtained to evaluate the fracture-
free survival rate and Cox proportional hazard model to
receive the corresponding hazard ratios (HR) and statistical
diﬀerences (P- v a l u e ) .T h em e a na n n u a lb o n el o s sr a t e( %
of baseline BMD) was calculated according to following
formulas:
annual BMD Change (ABC)
=

BMD at5-year follow-up −BMD at baseline

follow-up time
,
annual bone loss rate (% of baseline BMD)
=

ABC
BMD at baseline

×100.
(1)
The multivariate variables included (with references to
publications including detailed information on building
the covariate variables, if available, in brackets) are age,
baseline BMI, fracture history before the baseline (yes/no),
menopausestatusanduseofHT(yes/no),gripstrength[26],
alcohol intake (mg/day), smoking (yes/no) [28], nutritional
calcium intake (mg/day) [29], mother’s fracture (yes/no),
sister’s fracture (yes/no), and morbidities and medication
potentially aﬀecting bone (yes/no). The categorical variables
were entered into the Cox proportional hazards model as
indicator variables. Interaction analysis was performed by
entering the term [bone loss × variable] in to the Cox
model simultaneously with both independent variables. The
selection of conditions potentially aﬀecting bone (used
in covariate models) has been described previously by
Kr¨ oger etal. [21]. One combined dichotomous variable (any
bone-aﬀecting disease or medication/not any bone-aﬀecting
diseaseormedication)wasformedaccordingtoself-reported
morbidities and medications in the 5-year postal inquiry.
The diseases in this one dichotomous variable included renal
disease, liver disease, insulin-dependent diabetes, malignan-
cies,rheumatoidarthritis,endocrineabnormalities(parathy-
roid/thyroidglands,adrenals),malabsorption(includinglac-
tose malabsorption), total/partial gastrectomy, postovariec-
tomy status, premenopausal amenorrhea, alcoholism, and
long-term immobilization. The medication included: cor-
ticosteroids, thyroid medication, diuretics, cytotoxic drugs,
anticonvulsive drugs, anabolic steroids, calcitonin, bispho-
sphonates, and vitamin D. The percentage of women with
bone-aﬀecting diseases did not diﬀer signiﬁcantly between
the present study population (n = 1652) and total OSTPRE
population sample (37% versus 45%, resp., (P>. 100)).
3. Results
3.1. Characteristics of the Study Population. Table 1 describes
the baseline and follow-up characteristics according to the
mean annual bone loss rate tertiles. The tertiles of bone
loss rate were (1) high bone loss rate: over 0.84% per year,
(2) moderate bone loss rate: 0.13% to 0.84% per year, and
(3) low bone loss rate: under 0.13% per year. Women withJournal of Osteoporosis 5
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P = .177 (crude)/P = .502 (adjusted∗∗) between the tertiles
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∗∗Adjusted for all variables listed in Table 2
Figure 2: Cumulative 15-year fracture-free survival rate for any
fragility fracture according to annual bone loss rate (tertiles)∗.C o x
proportional hazard model (n = 1652).
high bone loss rate had signiﬁcantly less weight gain during
the baseline to 5-year measurement, less HT use, and more
bone-aﬀecting medications or diseases. Women with high
or moderate bone loss had lower grip strength compared
to women with low bone loss. In addition, the fracture
types according to study groups are presented in Table 1.
The statistically signiﬁcant diﬀerences in the characteristics
were taken into account by including them in multivariate
analyses of the present study.
3.2. Risk Factors for Fractures According to Bone Loss
Rate. Figure 2 represents the absolute fracture-free survival
according to bone loss tertiles in Cox proportional hazards
model. Accordingly, there were no diﬀerences in fracture-
free survival between the tertiles (P = .177 (univariate)/P =
.502 (adjusted) between high and low annual bone loss rate
tertiles).
Table 2 represents the risk factors for follow-up fractures
according to bone loss rate tertiles in uni- and multi-variate
Cox proportional hazards model. Among women with high
bone loss rate (over 0.84% per year) high T-score (P =
.012, HR = 0.707; 95% conﬁdence interval 0.539–0.927), no
sister’s fracture (P = .001, HR = 0.346; 0.187–0.641) and no
mother’s fracture (P = .015, HR = 0.518; 0.305–0.878) were
associatedwithlowerriskoffracturesinbothuni-andmulti-
variable models.
In women with moderate bone loss rate (0.13–0.84% per
year), high T-score (P = .008, HR = 0.692; 0.527–0.908) and
good grip strength (P = .022, HR = 0.982; 0.967–0.997) were
theonlysigniﬁcantpredictorsofhigherfracture-freesurvival
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Figure 3: Eﬀect of bone loss rate on fracture risk among women
with self-reported mother’s fracture. Cox proportional hazards
model (n = 319).
rate in multi-variate model. In univariate model, no use of
HT in postmenopause was additional signiﬁcant predictor of
higher fracture risk among these women (P<. 001).
Inwomenwithlowbonelossrate(under0.13%peryear)
there were no signiﬁcant predictors of fracture risk observed
among the variables investigated in multivariate model. In
univariate model high grip strength was the only signiﬁcant
predictor of higher fracture-free survival (OR = 0.986, 95%
conﬁdence interval 0.974–0.999, P = .032).
For the signiﬁcant predictors presented in Table 2,a
statistically signiﬁcant interaction was conﬁrmed for sister’s
fracture (P<. 001) and mother’s fracture (P = .020) in Cox
proportionalhazardsmodel.Basedontheseresults,theeﬀect
of bone loss on fracture risk was further investigated among
women with mother’s and sister’s fracture. In women with
sister’s fracture, high bone loss rate (over 0.84% per year)
p r e d i c t e dl o w e rf r a c t u r e - f r e es u r v i v a lr a t ei nc o m p a r i s o nt o
low bone loss rate (P = .039, OR = 2.656, 95% conﬁdence
interval 1.052–6.703) in multivariate model but not in
univariate model (P = .410). Figure 3 represents the eﬀect of
bone loss rate on fracture-free survival according to mother’s
fracture. Accordingly, high bone loss rate predicted lower
fracture-freesurvivalrateincomparisontolowbonelossrate
in univariate (OR = 2.703; 1.33–5.50, P = .006) and adjusted
multivariate (OR = 2.560; 1.15–5.70, P = .021) models. For
womenwithnosister’sormother’sfracturetheseeﬀectswere
not seen.6 Journal of Osteoporosis
Table 1: Characteristics according to study groups (annual bone loss tertiles, n = 1652).
Characteristics Bone loss tertiles∗
High (n = 551) Moderate (n = 547) Low (n = 553) Total (n = 1652)
(A) Means (SD) of continuous variables
Years since menopause (at 5 years) 7.7(5.1) 8.0(5.5) 8.3(6.1) 8.0(5.6)
Baseline age, years 53.5(2.8) 53.6(3.01) 53.6(2.9) 53.5(2.9)
Baseline height cm 161.4(5.3) 161.4(5.1) 161.1(5.0) 161.3(5.2)
Baseline weight kg 69.6(12.3) 69.1(11.6) 68.4(10.7) 69.0(11.6)
Weight change (Bl to 5 years), kg 2.1(5.3) 2.7(4.9) 4.2(5.1) 3.0(5.2)††
Grip strength kPA 62.6(16.0) 60.8(16.6) 64.7(16.4) 62.7(16.4)††
Calcium intake mg/day 797(294) 779(290) 809(284) 795(290)
Alcohol intake g/week 39.0(75.2) 48.2(76.3) 49.3(73.0) 45.52(75.0)†
Baseline FN T-score SD −0.30(1.05) −0.35(1.07) −0.54(1.09) −0.40(1.07)††
5-year FN T-score SD −0.99(0.99) −0.58(1.04) −0.33(1.12) −0.63(1.08)††
(B) Distribution of category variables (%)
Menopause status (at 5 years)
Premenopuasal (no HT) 13.1 8.2 7.8 9.7
Postmenopausal (no HT) 35.4 30.2 23.9 29.8
HT use 51.5 61.6 68.4 60.5††
No bone-aﬀecting disease/medication∗∗ 53.9 48.4 45.2 49.2†
Mother’s fracture 18.1 19.5 20.3 19.3
Sister’s fracture 9.6 10.3 11.4 10.5
Any previous fracture at 5 years 20.3 20.5 19.2 20.0
Smoking (never/ever) 19.2 17.4 18.4 18.4
Decline in grip strength (Bl to 5years) 28.3 22.9 24.3 25.2
Follow-up fractures 25.2 28.3 24.2 25.9
Wrist 9.4 9.1 8.5 9.0
Unimalleolar ankle 4.0 3.7 4.0 3.9
Other ankles 1.3 1.1 0.7 1.0
Lumbar/thoracal spine 2.4 2.0 1.3 1.9
Humerus 1.3 0.9 0.4 0.8
∗High: over 0.84% per year, moderate: 0.13% to 0.84% per year, low: under 0.13% per year. †P<. 05/ ††P< 0.01 in ANOVA (continuous variables) and
Chi square test (categorical variables) between the study groups. ∗∗For speciﬁcation of the diseases and medications included, see Materials and Methods—
Statistical Methods.
4. Discussion
The present study investigated the risk factors for early
postmenopausal fractures according to bone loss rate, in a
studycohortof1652Finnishwomen.Bonelossrateitselfwas
not a signiﬁcant predictor of fractures in total population.
However, the risk factors for low-trauma energy fractures
were found to diﬀer according to rate of bone loss. In women
with high bone loss rate, sister’s and mother’s fractures were
strongly related to increased fracture risk, in addition to
negative eﬀects of low baseline BMD. In women with low
bone loss rate, there were no signiﬁcant predictors found for
fracture risk in multivariate model. A statistically signiﬁcant
interaction with bone loss rate was observed for sister’s and
mother’s fracture. Accordingly, high bone loss rate was a
predictor of higher fracture risk among women with sister’s
or mother’s fracture.
The strengths of the present study included its prospec-
tive and population-based nature, large base population, and
long-term follow-up interval. Also, the present study setting
can be considered optimal for investigating the hypothesis
for present study. The BMD follow-up period was similar
between the study-groups, and bone mass and grip strength
measurements, as well as anthropometric measurements,
were performed under the supervision of trained personnel.
This may suppress occasional confounders due to mea-
surement errors. All the self-reported follow-up fractures
were validated from the medical records by study group
physicians. Finally, adjustment for bone-aﬀecting diseases
and medications with one combined dichotomous variable
(any bone-aﬀecting disease or medication/not any bone
aﬀecting disease or medication) was used in the multivariate
models, which may have weakened the possible bias caused
by varying sampling fractions. While the use of dichotomous
variable was not ideal for investigating the eﬀects of individ-
ual morbidities and medications, for adjustment purposes it
provided a practical choice in order to reduce the number of
covariates into minimum in multivariate models.Journal of Osteoporosis 7
Table 2: Predictors of 15-year fracture free-survival according to bone loss rate tertiles. Uni- and multi-variate Cox proportional hazards
models∗ (n = 1652).
Variables Univariate Sig. HR (95% CI) Multivariate Sig. HR (95% CI)
High bone loss rate
Grip strength 0.294 0.993(0.981–1.006) 0.290 0.992(0.977–1.007)
Grip strength change 0.200 1.501(0.807–2.791) 0.609 1.200(0.596–2.416)
No previous fracture 0.052 0.584(0.339–1.004) 0.472 0.785(0.406–1.518)
Age 0.348 0.965(0.895–1.040) 0.115 0.929(0.847–1.018)
Body mass index 0.174 0.964(0.914–1.016) 0.348 0.968(0.906–1.036)
Weight change 0.727 0.992(0.951–1.036) 0.433 0.980(0.932–1.031)
Use of HT∗∗ 0.866 0.919
Premenopausal (no HT) 0.748 1.106(0.598–2.047) 0.713 0.864(0.397–1.880)
Postmenopausal (no HT) 0.750 0.926(0.579–1.482) 0.969 1.012(0.559–1.832)
Bone-aﬀecting condition† 0.837 0.957(0.628–1.458) 0.917 1.030(0.594–1.785)
Nutritional calcium intake 0.859 1.000(0.999–1.001) 0.993 1.000(0.999–1.001)
Alcohol intake 0.808 1.000(0.997–1.003) 0.367 0.998(0.994–1.002)
Smoking 0.595 1.253(0.547–2.870) 0.619 1.266(0.500–3.201)
No sister’s fracture 0.000 0.358(0.204–0.630) 0.001 0.346(0.187–0.641)
No mother’s fracture 0.004 0.506(0.318–0.806) 0.015 0.518(0.305–0.878)
Bone mineral density 0.007 0.746(0.602–0.925) 0.012 0.707(0.539–0.927)
Moderate bone loss rate
Grip strength 0.003 0.983(0.972–0.994) 0.022 0.982(0.967–0.997)
Grip strength change 0.545 1.169(0.705–1.940) 0.667 0.881(0.494–1.572)
No previous fracture 0.091 0.630(0.369–1.076) 0.239 0.686(0.366–1.285)
Age 0.004 1.097(1.030–1.168) 0.516 1.027(0.947–1.115)
Body mass index 0.191 0.968(0.921–1.016) 0.782 0.991(0.929–1.057)
Weight change 0.721 0.993(0.953–1.034). 0.742 1.008(0.959–1.060)
Use of HT ∗∗ 0.000 0.104
Premenopausal (no HT) 0.154 0.428(0.134–1.373) 0.315 0.536(0.159–1.808)
Postmenopausal (no HT) 0.001 2.017(1.354–3.005) 0.104 1.579(0.910–2.742)
Bone-aﬀecting condition† 0.111 1.378(0.929–2.044) 0.416 1.249(0.731–2.133)
Nutritional calcium intake 0.752 1.000(0.999–1.000) 0.851 1.000(0.999–1.001)
Alcohol intake 0.843 1.000(0.997–1.002) 0.624 1.001(0.998–1.003)
Smoking 0.297 1.702(0.626–4.628) 0.583 1.341(0.470–3.825)
No sister’s fracture 0.055 0.563(0.313–1.014) 0.106 0.594(0.316–1.116)
No mother’s fracture 0.478 1.208(0.716–2.038) 0.460 1.258(0.684–2.313)
Bone mineral density 0.000 0.632(0.521–0.768) 0.008 0.692(0.527–0.908)
Low bone loss rate
Grip strength 0.032 0.986(0.974–0.999) 0.155 0.987(0.970–1.005)
Grip strength change 0.207 0.702(0.405–1.216) 0.147 0.621(0.327–1.182)
No previous fracture 0.064 0.559(0.302–1.035) 0.070 0.518(0.254–1.056)
Age 0.309 1.041(0.964–1.123) 0.904 1.006(0.917–1.102)
Body mass index 0.239 1.031(0.980–1.085) 0.778 1.011(0.935–1.095)
Weight change 0.166 1.029(0.988–1.071) 0.203 1.032(0.983–1.084)
Use of HT∗∗ 0.401 0.770
Premenopausal (no HT) 0.628 0.778(0.281–2.152) 0.984 0.988(0.308–3.173)
Postmenoapusal (no HT) 0.240 1.350(0.819–2.225) 0.504 1.267(0.634–2.531)
Bone-aﬀecting condition† 0.816 0.948(0.604–1.489) 0.791 0.918(0.487–1.730)
Nutritional calcium intake 0.053 0.999(0.999–1.000) 0.174 0.999(0.999–1.000)
Alcohol intake 0.758 0.999(0.996–1.003) 0.544 1.001(0.997–1.005)
Smoking 0.299 1.705(0.623–4.666) 0.294 1.904(0.572–6.335)
No sister’s fracture 0.065 0.544(0.285–1.039) 0.259 0.651(0.309–1.371)
No mother’s fracture 0.269 1.434(0.756–2.719) 0.710 1.142(0.567–2.299)
Bone mineral density 0.060 0.818(0.663–1.009) 0.105 0.785(0.585–1.052)
∗Bone loss tertiles: high: over 0.84% per year, moderate: 0.13% to 0.84% per year, low: under 0.13% per year. †Bone-aﬀecting disease or medication,
dichotomous variable (any disease or medication/not any disease or medication). See materials and Methods for details. ∗∗Reference group.8 Journal of Osteoporosis
A possibility of uncontrolled confounding is always
present in epidemiological studies. Although the study
sample of 2025 women was randomly selected from the
base population of 14220 women; the ﬁnal study sample
of 1652 women presented a relatively small part of the
original OSTPRE cohort. Accordingly, this heavy selection
process includes the risk that the ﬁnal sample may not
be fully representative of the underlying population. The
selection procedure may additionally cause lack of power.
T h ep e r c e n t a g e( 3 7 % )o fb o n e - a ﬀecting conditions was
high due to the wide spectrum of diseases or medications
considered to potentially have such properties. This variable
was, however, not associated with fracture risk in any of
the present analyses. Considering the predictive variables
in the present analyses, we used mean not maximum grip
strength which, however, may be equally consistent [30].
In addition, the deﬁnition of menopausal transition in the
present study was based purely on self-reports according to
amenorrhea, without information on hormonal levels. Self-
reports, however, have proved to be quite accurate in this
matter [31]. There were some diﬀerences in characteristics
between the study groups. As an example, women with
high bone loss rate had less weight gain and HT use. These
diﬀerences between the bone loss groups were taken into
account by adjustments in the multivariate models.
The present study used the baseline and 5-year BMD
measurements for deﬁning bone loss rate and it was used
to predict fractures between 5- to 15-year follow-up period.
In addition, 5-year postal inquiry information was used as
additional predictive data for fractures. The reason for the
use of only the ﬁrst two DXA measurements was the aim
to investigate the causal relationship between bone loss and
fractures. Accordingly, the possible changes in bone loss rate
during the fracture follow-up may have occurred.
Previously, several studies have found that ﬁrst-degree
relatives’ fractures, especially those of mother’s, are associ-
atedwiththepostmenopausalincidenceoffractures[13–18].
Inourpreviousreportweshowedthatsister’sfracturehistory
is, in general, associated with perimenopausal fractures [32].
The present study conﬁrms that sister’s fracture history is
a relevant determinant of perimenopausal fractures among
Finnish women but adds to this ﬁnding that bone loss may
interact with this genetic tendency for bone fragility. In
addition, the present study found that mother’s fractures
were negatively associated with fracture-free survival only
among women with high bone loss rate. It should be
remembered,however,thatquestionsconcerningtheparents
fracture history may provide less valid answers which may
contribute to the lack of association with fracture incidence
in other study groups. The background of the genetics of
fragility fractures has been reviewed recently [33]. Also,
sister’s and mother’s fractures showed signiﬁcant interaction
with bone loss rate in Cox model in the present study, and
especially among women with mother’s fracture, bone loss
was predictive for future fractures. This ﬁnding suggests
that among postmenopausal women with ﬁrst-degree female
relatives fractures bone loss may be used in evaluation
of fracture risk. In the present study, we also included
the relatives’ fractures during the follow-up, in addition
to previous fractures, for two reasons. Firstly, the history
of sister’s and mother’s wrist and hip fractures was not
questioned earlier than 10-year follow-up postal inquiry
in the present study. Secondly, it is unlikely that genetic
predisposition to fractures would be determined during the
present follow-up interval, thus eliminating the problem
with regards causality.
Our results indicate that bone loss rate as such is not
associated with increased fracture risk if abovementioned
risk fractures was not present. However, bone loss rate may
alter the eﬀects of other risk factors related to increased
fracturerisk.Inthepresentstudytheeﬀectsofsomelife-style
andanthropometric risk factorson fracturesweredependent
on bone loss rate. As an example, good grip strength seemed
to prevent fractures in women with moderate bone loss
rate. Grip strength has been previously shown to reﬂect
o v e r a l lp h y s i c a lp e r f o r m a n c e[ 34] and to be associated with
perimenopausalbonelossandincidenceoffractures[26,35].
Similarly, T-score was strongly predictive for fractures in
groups with moderate to high bone loss rate, but not among
womenwithlowbonelossrate.Ofthesepreviouslydiscussed
variables, a statistically signiﬁcant interaction was, however,
not conﬁrmed in Cox interaction model.
The use of hormone therapy should not be considered
primary medication for osteoporosis because of possible
serious adverse events [36] and also due to the introduction
ofnewereﬀectivenonhormonalbonemedications.However,
there still may be indications for HT in other than bone
relatedconditionsforperimenopausalwomen.Inthepresent
study, we aimed primarily at using HT as a confounder of
menopause status rather than as a preventive medication
for fractures or low bone mass. In the present study HT
was protective against fragility fractures only in women with
moderate bone loss in univariate model. In multivariate
model this eﬀect was not seen which suggests that other
factors may outweigh HTs eﬀe ct s .T h ebo n ep r o t e cti v ee ﬀects
and biology of HT have been studied in detail previously
[37, 38].
The purpose of the present study was to demonstrate
that risk factors for fractures diﬀer according to bone loss
rate. The current diagnosis and deﬁnition of osteoporosis
is based on BMD measurements, although it has been
speculated that bone quality, including several other aspects
of bone biology apart from BMD, is a more appropriate
measure. As an example, it has been stated that only 44%
of nonvertebral fractures occur among osteoporotic women
while the majority of these fractures occur in women with
higher BMD [39]. This fact underlines the need to evaluate
fracture risk more holistically than BMD alone and suggests
that there are several other properties of bone involved
in high fragility [40, 41]. However, the interaction of risk
factors for fragility fractures with bone loss rate, observed in
the present study, may indicate that bone loss rate reﬂects
additional properties of bone health besides single BMD
measurement. To our knowledge, this is the ﬁrst population-
based long-term follow-up study to show that risk factors
for fragility fractures are dependent on rate of bone loss in
postmenopausal women with especially strong interaction
with ﬁrst-degree female relative’s fractures.Journal of Osteoporosis 9
In conclusion, the risk factors for fragility fractures
seem to interact with bone loss rate among perimenopausal
women. In women with high bone loss rate, there may be
especially strong genetic predisposition to increased bone
fragility. Also, in women with low bone loss rate, BMD
seems not to predict fractures in contrast to women with
moderate to high bone loss rate. It may be concluded that
while bone mass measurements do not fully explain bone
fragility among elderly women, it may reveal diﬀerences in
response to other fracture risk factors. However, bone loss
rate, as such, may not be considered predictive for fractures
without contribution of other concomitant risk factors, such
as ﬁrst-degree female relatives fractures. These results should
be conﬁrmed in other populations and also among elderly
males.
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